Relationship between ETS Transcription Factor ETV1 and TGF-β-regulated SMAD Proteins in Prostate Cancer

Sangphil Oh, Sook Shin, Hoogeun Song, Joseph P. Grande & Ralf Janknecht

The ETS transcription factor ETV1 is frequently overexpressed in aggressive prostate cancer, which is one underlying cause of this disease. Accordingly, transgenic mice that prostate-specifically overexpress ETV1 develop prostatic intraepithelial neoplasia. However, progression to the adenocarcinoma stage is stifled in these mice, suggesting that inhibitory pathways possibly preclude ETV1 from exerting its full oncogenic potential. Here we provide evidence that TGF-β/SMAD signaling represents such an inhibitory pathway. First, we discovered that ETV1 forms complexes with SMAD4. Second, SMAD2, SMAD3 and SMAD4 overexpression impaired ETV1’s ability to stimulate gene transcription. Third, TGF-β1 inhibited ETV1-induced invasion by benign RWPE-1 prostate cells. Fourth, increased expression of SMAD3 and SMAD4 was observable in prostates of ETV1 transgenic mice. Conversely, we found that ETV1 may enhance TGF-β signaling in PC3 prostate cancer cells, revealing a different facet of the ETV1/TGF-β interplay. Altogether, these data provide more insights into the regulation and action of ETV1 and additionally suggest that TGF-β/SMAD signaling exerts its tumor suppressive activity, at least in part, by curtailing the oncogenic potential of ETV1 in prostatic lesions.

The oncogenic transcription factor ETS variant 1 (ETV1) becomes overexpressed in many prostate tumors by chromosomal translocations involving the ETV1 gene and androgen-responsive promoters1-4 or by loss of its negative regulator, the ubiquitin ligase COP15,6. Overexpression of ETV1 increased migration and invasion by benign prostate cells2,5,7-9, stimulated androgen metabolism10, and correlated with higher disease recurrence and reduced survival in prostate cancer patients10,11. In addition, a small molecule inhibitor of ETV1 suppressed prostate cancer cell proliferation in vitro and in vivo2,13. All this suggests that ETV1 is required for efficient growth and aggressiveness/metastasis during prostate cancer progression.

In line with this, ETV1 overexpression can lead to increased transcription of the matrix metalloproteinase 1 (MMP1) and MMP7 genes14-16, which both are important for cancer cell invasion. Also, transgenic mice overexpressing ETV1 in the prostate presented with prostatic intraepithelial neoplasia (PIN), yet deficiency of the tumor suppressor PTEN, which is commonly observed in human prostate tumors, was additionally required for the development of prostate adenocarcinomas in ETV1 transgenic mice2,10,11,17. Interestingly, transcriptional activity of ETV1 can be vastly enhanced by mitogen-activated protein kinase signaling pathways through post-translational modification of ETV114,18-21, suggesting that not only overexpression, but also stimulation of its transcriptional potential may be involved in facilitating ETV1’s oncogenic role.

One unresolved question is why ETV1 transgenic mice did not progress from PIN to the adenocarcinoma stage. A similar question related to the homozygous deletion of the tumor suppressor PTEN in the prostate of mice, which led to PIN, but only after a long latency induced adenocarcinomas that rarely metastasized22,23. However, deletion of SMAD4 in addition to PTEN invariably resulted into the development of metastatic, lethal prostate cancer at an early age, whereas SMAD4 ablation on its own reportedly did not cause any prostatic lesions24. These data suggested that SMAD4 is a barrier that can prevent progression of prostate tumorigenesis.

1University of Oklahoma Health Sciences Center, Department of Cell Biology, Oklahoma City, OK, 73104, USA.
2Stephenson Cancer Center, Oklahoma City, OK, 73104, USA. 3Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, 55905, USA. 4University of Oklahoma Health Sciences Center, Department of Pathology, Oklahoma City, OK, 73104, USA. Correspondence and requests for materials should be addressed to R.J. (email: ralf-janknecht@ouhsc.edu)
Notably, SMAD4 is a downstream effector of transforming growth factor β (TGF-β), a cytokine with tumor suppressive activity. TGF-β induces the phosphorylation of SMAD2 and SMAD3 at the plasma membrane, which causes their association with SMAD4 and translocation to the cell nucleus where these DNA-binding proteins regulate the activity of a variety of genes. Here, we explored if TGF-β and SMAD proteins might also repress the oncogenic potential of ETV1.

Results

Interaction of ETV1 with SMAD proteins. To study a potential interaction of ETV1 with SMAD proteins, we coexpressed Myc-tagged ETV1 with Flag-tagged SMAD proteins and performed immunoprecipitations with anti-Flag antibodies. Any coprecipitated ETV1 was then detected by anti-Myc western blotting (Fig. 1a and Supplementary Fig. S1). Indeed, ETV1 coimmunoprecipitated with SMAD4, but not with SMAD1, SMAD2 or SMAD3. We then confirmed that bacterially expressed and purified GST-SMAD4, but not a comparable amount of the GST moiety, also interacted with ETV1 (Fig. 1b,c), suggesting that SMAD4 and ETV1 directly bind to each other. Moreover, we determined that the N-terminal half of SMAD4, which encompasses its DNA-binding MH1 domain, was responsible for binding ETV1 (Fig. 1c,d).

Conversely, we examined which amino acids in ETV1 are required for its interaction with SMAD4. Truncating ETV1 from the C-terminus down to amino acid 429 (ETV1 2–429) did not impact on the binding to SMAD4, but further truncation down to amino acids 333 or 249 abolished this interaction (Fig. 2 and Supplementary Fig. S1). Likewise, we truncated ETV1 from the N-terminus and found that the first 248 amino acids were dispensable for SMAD4 binding (see 182–477 and 249–477 in Fig. 2). However, the 333–477 truncation did not bind to SMAD4. This suggested that amino acids 249–429 mediate the interaction with SMAD4. And indeed, ETV1 amino acids 249–429 were sufficient for binding to SMAD4, whereas amino acids 249–383 were not (Fig. 2). Overall, these data indicate that neither the N- nor C-terminal ETV1 activation domain is required for binding to SMAD4, whereas both the DNA-binding ETS domain and amino acids 249–333 of ETV1 are needed for establishing an ETV1-SMAD4 complex.

Inhibition of ETV1 transcriptional activity by SMAD proteins. Next, we tested whether transcriptional activity of ETV1 can be modulated by interaction with SMAD proteins. To do so, we first utilized an MMP1 reporter gene in 293T cells and expressed SMAD proteins and/or ETV1 (Fig. 3a, left panel). MMP1 reporter gene activity was increased by overexpression of ETV1 as previously reported, but this was blunted by SMAD4, suggesting that binding to SMAD4 represses the transcriptional activity of ETV1. Interestingly, SMAD2 and SMAD3 also repressed ETV1’s activity although they did not bind ETV1 in our overexpression system as shown in Fig. 1a; please see Discussion for possible explanations. On the other hand, SMAD1, which is not downstream...
of TGF-β but rather of bone morphogenetic proteins\textsuperscript{27}, had no impact on ETV1-dependent transcription (Fig. 3a, left panel). We also assessed MMP1 transcription upon overexpression of oncogenic HER2 that greatly stimulates ETV1 activity\textsuperscript{14}. Again, we observed that SMAD2-4 repressed ETV1-dependent activity (Fig. 3a, right panel) and even SMAD1 did so, albeit in the least pronounced manner.

In addition, we tested whether induction of endogenous MMP1 would also be suppressed by SMAD proteins in 293T cells. As previously reported\textsuperscript{14}, robust MMP1 mRNA induction by ETV1 was achieved through coexpression of oncogenic HER2. When either SMAD3 or SMAD4 were coexpressed, the ETV1-mediated induction of endogenous MMP1 was suppressed (Fig. 3b, left panels, and Supplementary Fig. S2). Similarly, SMAD2 suppressed ETV1 activity, but SMAD1 did not (Fig. 3b, right panels, and Supplementary Fig. S2). These data largely corroborate our luciferase reporter gene assays and demonstrate that the TGF-β downstream effectors, SMAD2, SMAD3 and SMAD4, can inhibit ETV1-mediated transcription.

To assess the impact of TGF-β signaling on ETV1 activity, we also employed a constitutively activated TGF-β receptor I (TGFBR1). Its coexpression reduced ETV1-dependent, HER2-stimulated MMP1 luciferase reporter gene activity (Fig. 3c) and endogenous MMP1 transcription (Fig. 3d and Supplementary Fig. S2). These data further validate that TGF-β signaling can suppress ETV1’s ability to stimulate gene transcription.

**Impact of TGF-β on ETV1-stimulated invasion by RWPE-1 cells.** To assess whether TGF-β signaling modulates physiological effects mediated by ETV1, we utilized benign human prostate RWPE-1 cells and generated respective ETV1 overexpressing stable cells (Fig. 4a and Supplementary Fig. S2); no changes in SMAD3 or SMAD4 protein levels were observable upon ETV1 overexpression. Then, we determined the growth of these cells and found it to be inhibited by TGF-β\textsubscript{1}, but this was independent of ETV1 overexpression (Fig. 4b). In contrast, cell invasion in the absence of ectopic ETV1 was not affected by TGF-β\textsubscript{1}, but TGF-β\textsubscript{1} suppressed the pro-invasive activity of ETV1 (Fig. 4c,d); this suppression was blunted upon SMAD4 downregulation (Supplementary Fig. S3). These data support the notion that TGF-β signaling can restrain ETV1 activity.

**Impact of ETV1 on TGF-β signaling in PC3 cells.** We were curious whether ETV1 might conversely affect TGF-β signaling. To test this, we utilized human PC3 prostate cancer cells, which express high levels of endogenous ETV1 and are not deficient in TGF-β signaling. Thus, we downregulated ETV1 with two different shRNAs, then induced cells with TGF-β\textsubscript{1} and measured the expression of known TGF-β-regulated genes, the plasminogen activator inhibitor-1 (PAI-1), the cell cycle inhibitor p21 and the TGF-β signaling regulator PMEPAL\textsuperscript{25,26,28}. Of note, ETV1 downregulation suppressed the induction of expression of all these three genes by TGF-β\textsubscript{1} (Fig. 5 and Supplementary Fig. S4). No changes of cyclin D1, SMAD3 or SMAD4 protein levels were observed, whereas expectedly phosphorylation of SMAD3 was induced upon TGF-β\textsubscript{1} administration and this was not affected by ETV1 shRNAs. These data suggest that, in addition to TGF-β suppressing ETV1 activity, ETV1 can promote TGF-β signaling.

We also overexpressed ETV1 in PC3 cells in order to determine whether this would enhance expression of TGF-β regulated genes. However, this did not affect PAI-1 protein levels upon TGF-β\textsubscript{1} administration, yet moderately increased p21 expression (Supplementary Fig. S4), the latter supporting our hypothesis that ETV1 is a promoter of TGF-β signaling. Further, SMAD4 shRNA basically abrogated the induction of PAI-1 and p21 by TGF-β\textsubscript{1}, confirming that these genes are indeed regulated through SMAD4 (Supplementary Fig. S4). The fact that
endogenous ETV1 is already highly expressed in PC3 cells probably accounted for the fact that additional, ectopic ETV1 had no or only a modest effect on TGF-β-mediated gene expression.

Analysis of ETV1 transgenic mice and human prostate tumors. To analyze the relationship between ETV1 and SMAD proteins in vivo, we harnessed ETV1 transgenic mice that develop PIN. First, we stained their prostates for SMAD3 and SMAD4. While there was little expression of either protein in prostates from control mice (please note that we utilized Smad4f/f mice as controls), both SMAD3 and SMAD4 levels were enhanced in prostates from age-matched ETV1 transgenic mice (Fig. 6a and Supplementary Fig. S5). This indicates that SMAD3/4 are present to potentially restrain the oncogenic activity of overexpressed ETV1 in the prostate.

We then asked the question what would happen when SMAD4 becomes ablated. To this end, we crossed transgenic ETV1 mice with conditional SMAD4 knockout mice (Smad4f/f) and a prostate specific Cre recombinase driver mouse (Pb-Cre4). As expected, PIN formation was significantly enhanced in ETV1 mice (Fig. 6b and Supplementary Fig. S6). Please note that we utilized Smad4f/f mice as a control and many of them developed low-grade PIN, which is identical to what we observed in old age wild-type mice. Likewise, Pb-Cre4;Smad4f/f mice displayed significantly enhanced PIN formation, which is in contrast to a previous report stating that no prostatic lesions were observable. Regardless, ETV1;Pb-Cre4;Smad4f/f compound mice did not develop prostate adenocarcinomas and the degree of high-grade PIN formation was similar to ETV1 and Pb-Cre4;Smad4f/f mice (Fig. 6b and Supplementary Fig. S6). These data suggest that SMAD4 ablation does not promote prostate tumor formation upon ETV1 overexpression (but see Discussion).

Lastly, we studied the expression of SMAD2, SMAD3 and SMAD4 in published human microarray data sets with the help of Oncomine (www.oncomine.org). SMAD2 mRNA levels were significantly downregulated in prostate carcinomas compared to normal prostate tissue, and even more so at metastatic compared to primary tumor sites (Fig. 7a,b and Supplementary Fig. S7). The same was true for SMAD3 and SMAD4 (Fig. 7c-f).
and Supplementary Fig. S7), and low SMAD4 expression was even significantly associated with recurrence and lethality (Fig. 7g,h). Furthermore, SMAD3 and SMAD4 were also downregulated in human prostate tumors being positive for ETV1 gene fusions (Supplementary Fig. S7). On the other hand, we did not find compelling evidence for SMAD1 downregulation in prostate cancer; rather, SMAD1 mRNA levels may even be upregulated in prostate carcinomas (Supplementary Fig. S7). These bioinformatics results implicate that SMAD2, SMAD3 and SMAD4 may exert tumor suppressive functions in the prostate, including the inhibition of ETV1’s oncogenic activity.

**Discussion**

In this report, we identified SMAD4 as a novel interaction partner of ETV1 that can repress ETV1-mediated transcription, providing a mechanism by which TGF-β signaling may constrain ETV1’s oncogenic activity. Furthermore, our data indicate that ETV1 may be needed for maximal TGF-β activity in prostate cancer cells. This suggests a model whereby ETV1 overexpression in the prostate in part limits its own oncogenic potential by activating the tumor suppressive power of TGF-β; but upon SMAD4 (or SMAD2 or SMAD3) downregulation or inactivating mutation, ETV1’s oncogenic activity becomes fully competent and this is needed for the progression of PIN to carcinoma in the prostate (Fig. 8).

Analysis of published microarray data revealed that SMAD2, SMAD3 and SMAD4 mRNA levels decrease during prostate tumorigenesis, implying that loss of their expression could contribute to the progression of PIN to localized carcinoma and then to metastasis. These observations are consistent with previous reports showing that SMAD4 protein and mRNA levels are reduced in prostate carcinomas compared to normal prostate tissue. Notably, SMAD3 and likely also SMAD4 interact with the androgen receptor, which may activate or repress androgen-inducible gene transcription in a promoter-dependent manner. This interaction with the androgen receptor is mediated through the MH2 domain of SMAD4, whereas the MH2 domain of SMAD4 is dispensable for binding to ETV1. Furthermore, ETV1 is capable of binding to the androgen receptor, which entails ETV1 amino acids 182–477 and thus encompasses amino acids 249–429 that mediate the ETV1-SMAD4 interaction. Hence, it remains to be studied whether SMAD4 and androgen receptor binding to ETV1 are mutually exclusive, or whether a ternary complex can exist.
At present, we do not know how SMAD2 and SMAD3 repressed ETV1-dependent transcription despite the fact that we did not detect coimmunoprecipitation of ETV1 with SMAD2 or SMAD3. However, it is possible that their interaction is of low affinity that precludes detection in coimmunoprecipitation assays. Or alternatively, SMAD4 is needed to facilitate any interaction of ETV1 with SMAD2 and SMAD3, and the amount of endogenous SMAD4 in 293T cells may be too low to result into detectable levels of ETV1-SMAD2/3 complexes. Regardless, the bone morphogenetic protein-regulated SMAD1 transcription factor, which also did not coimmunoprecipitate with ETV1, was incapable of suppressing ETV1-dependent activation of the endogenous MMP1 promoter. The ETV1 blot was derived from the stripped PAI-1 blot, the p-SMAD3 blot from the stripped SMAD4 blot, the SMAD3 blot from the stripped cyclin D1 blot, and the actin blot from the stripped SMAD3 blot.

Figure 5. Regulation of TGF-β-dependent gene expression by ETV1. PC3 prostate cancer cells stably expressing control shRNA or two different ETV1 shRNAs were treated with TGF-β1 for 0, 4, 8 or 24 hours. Western blots for indicated proteins are shown. Full-length blots are presented in Supplementary Fig. S4. Blots for PAI-1 and p21 were derived from the same gel cut at ~34 kDa. Similarly, blots for SMAD4 and PMEPA1 were derived from another gel cut at ~43 kDa. A third gel was utilized for cyclin D1 blotting. The ETV1 blot was derived from the stripped PAI-1 blot, the p-SMAD3 blot from the stripped SMAD4 blot, the SMAD3 blot from the stripped cyclin D1 blot, and the actin blot from the stripped SMAD3 blot.

At present, we do not know how SMAD2 and SMAD3 repressed ETV1-dependent transcription despite the fact that we did not detect coimmunoprecipitation of ETV1 with SMAD2 or SMAD3. However, it is possible that their interaction is of low affinity that precludes detection in coimmunoprecipitation assays. Or alternatively, SMAD4 is needed to facilitate any interaction of ETV1 with SMAD2 and SMAD3, and the amount of endogenous SMAD4 in 293T cells may be too low to result into detectable levels of ETV1-SMAD2/3 complexes. Regardless, the bone morphogenetic protein-regulated SMAD1 transcription factor, which also did not coimmunoprecipitate with ETV1, was incapable of suppressing ETV1-dependent activation of the endogenous MMP1 promoter, implicating that only the TGF-β-regulated SMADs affect ETV1. Interestingly, the bone morphogenetic protein signaling pathway exerts an opposite role to TGF-β signaling in the development of prostate cancer43, and maybe the differential functional interaction of ETV1 with SMAD1 and SMAD2/3 is one underlying cause for this.

We attempted to prove that ETV1 overexpression cooperates with SMAD4 loss in the development of prostate cancer by emulating such a situation with our ETV1;Pb-Cre4;Smad4f/f compound mice. However, these mice were no different from ETV1 or Pb-Cre4;Smad4f/f mice and developed only high-grade PIN, but not prostate adenocarcinoma. Similarly, an attempt to show cooperation between ETV1 and JMJD2A, another interaction partner of ETV1, with respective transgenic mice had failed; however, their cooperation in prostate carcinoma formation was revealed in a background of Pten+/− mice15. Human prostate tumors normally display several mutations at one time44, and it has been estimated that three or more driver mutations are required for the development of solid tumors45. Accordingly, ETV1 overexpression combined with loss of SMAD4 may be insufficient for
carcinoma development, and future studies should focus on the analysis of, for instance, ETV1;Pb-Cre4;Smad4f/f; Pten+/− mice to examine whether SMAD4 loss allows overexpressed ETV1 to induce prostate adenocarcinomas in the context of more genetic changes.

Notably, we observed that SMAD3 and SMAD4 protein levels were enhanced in prostates of ETV1 transgenic mice. This implies that ETV1 overexpression restrains its own oncogenic impact, at least during the initial PIN phase of prostate tumorigenesis, by causing SMAD3/4 overexpression. Although we have not investigated the mechanism, one speculation is that interaction with ETV1 might stabilize SMAD proteins, similar as has been observed for SMAD3 and another ETS transcription factor, the ERG oncoprotein46. However, in contradiction to this hypothesis, we observed no alteration of SMAD3/4 protein levels in PC3 prostate cancer cells upon ETV1 downregulation (see Fig. 5) or in RWPE-1 cells upon ETV1 overexpression (see Fig. 4a); this has the caveat that PC3 and RWPE-1 cells are of human and not mouse origin and that in vitro cell culture does not always mimic a complex organ such as the prostate. Regardless, this implies the existence of a mechanism different from SMAD stabilization by which ETV1 overexpression could exacerbate, at least in cell culture, TGF-β signaling and its tumor suppressive function. Further, the impact of ETV1 on TGF-β signaling may not be limited to prostate cancer, but pertain to many other normal and diseased tissues where TGF-β exerts important functions during development, homeostasis and pathogenesis.

In conclusion, this study has revealed a novel relationship between ETV1 and TGF-β/SMAD4, which may explain why ETV1 overexpression on its own is insufficient to cause the development of prostate adenocarcinomas. Because ETV1 is not only implicated in prostate cancer, but also many other malignancies such as melanoma, breast and gastrointestinal stromal tumors47, the insights provided here will likely have relevance beyond prostate cancer. Lastly, ETV4 and ETV5 are highly homologous to ETV1 and also implicated in prostate cancer development48. Hence, we predict that ETV4 and ETV5 are also negatively regulated by TGF-β signaling.

Methods

DNA constructs, chemicals, enzymes and antibodies. All DNA constructs were made in the corresponding author’s laboratory and verified by DNA sequencing and/or restriction enzyme analysis. Chemicals were purchased at molecular biology or analytical grade purity from established vendors (e.g., Sigma-Aldrich, VWR). Enzymes were obtained from Promega or New England Biolabs. The following antibodies were used for western blotting or immunoprecipitation: anti-Flag M2 (Sigma-Aldrich F1804), anti-Myc 9E10 (Sigma-Aldrich M4439), anti-cyclin D1 DCS6 (Cell Signaling #2926), anti-SMAD4 B-8 (Santa Cruz sc-7966) and anti-actin (GenScript A00730) mouse monoclonal antibodies; anti-ETV1 (Abcam ab81086 or our previously described #9520) rabbit monoclonal antibodies. SMAD3 (Zymed 51–1500) rabbit polyclonal antibodies; and anti-p-SMAD3-Ser423/425 C25A9 (Cell Signaling #9520) rabbit monoclonal antibodies.

Coimmunoprecipitation assay. Human embryonic kidney 293T cells were transiently transfected with indicated expression vectors by the calcium phosphate coprecipitation method49. Two days later, coimmunoprecipitations were performed essentially as described49 employing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 50 mM NaF, 0.5% Igepal CA-630, 1 mM PMSE, 10 µg/ml leupeptin, 2 µg/ml apropinin, 1 µg/ml pepstatin A, 0.1 mM DTT for cell lysis and washing procedures. Coprecipitated proteins were then detected by western blotting.

Preparation of protein extracts. Human 293T cells were grown in 6-cm plates and transiently transfected by the calcium phosphate coprecipitation method50 utilizing 4 µg of 6Myc-tagged ETV1 expression constructs51 and 5 µg of pBluescript KS+ as a carrier. 36 h after transfection, cells were lysed in 300 µl of 10 mM Tris-HCl, 0.5% Igepal CA-630, 1 mM PMSF, 10 µg/ml leupeptin, 2 µg/ml apropinin, 1 µg/ml pepstatin A, 0.1 mM DTT for cell lysis and washing procedures. Coprecipitated proteins were then detected by western blotting.
30 mM Na₄P₂O₇ (pH 7.1), 50 mM NaF, 0.5 mM Na₃VO₄, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, 10 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin A, 1 mM DTT for 30 min on ice. After a clear spin, the supernatants were frozen in liquid nitrogen and stored at −80 °C. Approximately 5–20 µl of these protein extracts were employed for GST pull-down assays.

**GST pull-down assay.** Glutathione S-transferase (GST) fusion proteins were produced employing standard procedures. Then, GST fusion proteins were bound to 20 µl of glutathione agarose beads in 650 µl of 20 mM HEPES (pH 7.4), 25 mM NaCl, 0.01% Tween-20, 1 mM DTT, 0.4 mM PMSF, 10 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin A for 2 h at 4 °C. Thereafter, beads were washed twice before incubation with protein extracts and 650 µl of the above mentioned binding buffer. 3 h later, beads were washed three times and bound proteins boiled in Laemmli buffer. Finally, SDS polyacrylamide gel electrophoresis was performed and proteins transferred to PVDF membrane. Subsequent incubation with primary and secondary antibodies as well as detection with chemiluminescence was done essentially as described.

**Luciferase assays.** Human 293T cells were grown in poly-L-lysine coated 12-wells and transiently transfected with 100 ng MMP1-luciferase reporter plasmid, 900 ng pBluescript KS+, 5 ng empty vector pEV3S or ETV1 expression plasmid, 10 ng empty vector pEV3S or SMAD expression plasmid, and 2 ng empty vector pQCX1H or pQCX1H-HER2/Neu-V664E expression plasmid utilizing 2 µg polyethylenimine. For Fig. 3c, alternatively 10 ng empty vector pEV3S or ETV1 expression plasmid, 15 ng empty vector pcDNA3 or TGFBR1-T204D

---

**Figure 7.** Altered expression of SMAD2, SMAD3 and SMAD4 in prostate cancer. All data were derived with Oncomine from published microarray experiments. (a) SMAD2 mRNA levels (probe 203075_at) in normal prostate tissue and prostate adenocarcinoma. Data from Wallace et al. (b) SMAD2 mRNA levels (probe 1928_s_at) in prostate tumors at primary and metastatic sites. Data from Holzbeierlein et al. (c) SMAD3 mRNA levels (probe 10217) in normal prostate tissue and prostate carcinoma. Data from Taylor et al. (d) SMAD3 mRNA levels (probe 38944_at) in prostate tumors at primary and metastatic sites. Data from Yu et al. (e) SMAD4 mRNA levels (probe IMAGE:321958) in normal prostate tissue and prostate carcinoma. Data from Tomlins et al. (f) SMAD4 mRNA levels (probe 509_at) in prostate tumors at primary and metastatic sites. Data from Yu et al. (g) Recurrence and (h) survival 5 years after diagnosis are correlated with SMAD4 mRNA levels (probe GI_3417555-S). Data from Nakagawa et al. Shown are means with standard deviations. Number of samples is given in parentheses. Unpaired, two-tailed t test was used to assess statistical significance in all panels.
(constitutively active TGF-β receptor I) expression plasmid, and 2 ng empty vector pQCXIH or pQCXIH-HER2/Neu-V664E expression plasmid were used. The transfection mixture was washed away with phosphate-buffered saline 8 h later and after another 36 h, cells were lysed and luciferase activities measured as described before61.

RT-PCR. RNA was isolated as described before62. This RNA was utilized for cDNA synthesis and amplification by PCR9. MMP1 expression was revealed with primers 5′-GTTCAGGGACAGAATGTGCTA-3′ and 5′-CTGCAGTTGAACCAGCTATTAG-3′ that yielded a 350 bp cDNA product. Primers for GAPDH were 5′-GAGCCACATCGCTCAGACACC-3′ and 5′-TGACAAGCTTCCGTTCTCAGC-3′ (226 bp cDNA product)63. Amplified cDNA was revealed after agarose gel electrophoresis by staining with ethidium bromide64.

Cell growth and invasion assays. Retrovirus was produced with the pQCXIN empty vector or pQCXIN-hETV1 expression plasmid as described before65. After twice infecting RWPE-1 cells, transduced cells were selected66 with 500 µg/ml G418 in keratinocyte serum free media (GIBCO) supplemented with 0.05 mg/ml bovine pituitary extract and 5 ng/ml human recombinant epidermal growth factor. For cell growth assays, 5×10^3 RWPE-1 cells were seeded in 24-well plates and growth was monitored utilizing the PrestoBlue cell viability kit (Invitrogen)67 in the presence or absence of TGF-β1 (10 ng/ml). For cell invasion, 5×10^4 RWPE-1 cells (pre-treated with 10 µg/ml mitomycin C for 2 h) were plated on Matrigel invasion chambers (Corning, 8-µm pores) in keratinocyte serum free media containing 0.1% bovine serum albumin in the presence or absence of TGF-β1 (10 ng/ml) and placed into 24-well plates containing keratinocyte serum free media supplemented with 0.05 mg/ml bovine pituitary extract and 5 ng/ml human recombinant epidermal growth factor. After 60 h, non-invaded cells were removed with a cotton swab, invaded cells fixed with methanol, stained with Hemacolor Stain Set (Harleco) and then counted.

Mouse experiments. All work with mice was approved by the University of Oklahoma Health Sciences Center Institutional Animal Care and Use Committee and was performed in accordance with local and federal guidelines and regulations. Transgenic ETV1 mice were described before11 and maintained on a C57BL/6 background. Smad4f/f conditional knockout mice (Smad4 tm2.1Cxd/J; 017462)68 were obtained from Jackson Laboratories, while Pb-Cre4 mice were obtained from the NCI Mouse Repository (B6.Cg-Tg(Pbsn-cre)4Prb/Nci; 01XF5). Please note that only male Pb-Cre4 mice were utilized for generating the compound mice, since low levels of Cre recombinase expression in oocytes could result in deletion of floxed alleles in all organs. Mice were bred on a mixed background. ETV1; Pbc-Cre4; Smad4f/f, ETV1; Pbc-Cre4; Smad4f/f, or Pbc-Cre4; Smad4f/f males were bred with Smad4f/f or ETV1; Smad4f/f females to establish experimental male cohorts. Genotyping of mice was done by standard PCR of tail-snip DNA69. To detect the Pbc-Cre4 transgene, primers 5′-CTGAGAGATGGGACACGCTTG-3′ and 5′-CATCAGGGTCATCGGACC-3′ (393 bp DNA product) were used. To analyze Smad4 status, primers 5′-TAAGAGGCACAGGTCAAGC-3′ and 5′-TTCCAGGAAAACAGGCTA-3′ (436 bp for wild-type and ~500 bp for floxed allele) were utilized. Primers for ETV1 genotyping were described before11.

Figure 8. Model showing the relationship between TGF-β/SMAD signaling and ETV1 during prostate tumorigenesis. The mechanism how ETV1 impinges on SMAD-dependent transcription is unknown.
Prostates were fixed with formaldehyde and embedded in paraffin. Then three slides of 4 µm thickness were cut that were 20 µm apart. These slides were stained with H&E and analyzed for lesions utilizing an established PIN grading system

Immunohistochemistry. All staining procedures were performed with a Leica BOND-III machine. An initial 20 min treatment with Bond EpiTope Retrieval Solution 1 (Leica Biosystems) was employed, followed by staining with anti-SMAD4 B-8 (Santa Cruz sc-79666) mouse monoclonal antibodies at a 1:200 dilution or with anti-SMAD3 (Zymed 51–1500) rabbit polyclonal antibodies at a 1:250 dilution. After incubation with appropriate secondary antibodies coupled to hors eradish peroxidase, 3,3′-diaminobenzidine staining occurred. The stained slides were digitized and digital images extracted with Aperio ImageScope software (Leica). Light transmission was measured with ImageJ software/Fiji (http://fiji.sc) after color deconvolution. Intensity of staining was defined as the difference between the logarithm of maximum light transmission and the logarithm of mean light transmission.

Data Availability
Data, detailed protocols and DNA constructs will be made available upon reasonable request. Transgenic ETV1 mice are not available, because they are no longer maintained; however, the plasmid to generate these transgenic mice is available upon reasonable request.

References
1. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
2. Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595–599 (2007).
3. Hermans, K. G. et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 68, 7541–7549 (2008).
4. Attard, G. et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br. J. Cancer 99, 314–320 (2008).
5. Baert, J. L. et al. The E3 ubiquitin ligase complex component COP1 regulates PEA3 group member stability and transcriptional activity. Oncogene 29, 1810–1820 (2010).
6. Citardi, M. et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 474, 403–410 (2011).
7. Cai, C. et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol. Endocrinol. 21, 1835–1846 (2007).
8. Hellenhorst, P. C. et al. Oncogenic ETS proteins mimic activated RAS/RAF signaling in prostate cells. Genes Dev. 25, 2147–2157 (2011).
9. Oh, S., Shin, S., Lightfoot, S. A. & Janknecht, R. 14-3-3 proteins modulate the ETS transcription factor ETV1 in prostate cancer. Cancer Res. 73, 5110–5119 (2013).
10. Baena, E. et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 27, 683–698 (2013).
11. Shin, S. et al. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res. 69, 8102–8110 (2009).
12. Rahim, S. et al. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One 6, e19343 (2011).
13. Rahim, S. et al. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model. PLoS One 9, e114260 (2014).
14. Bosc, D. G., Goueli, B. S. & Janknecht, R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP1. Oncogene 20, 6215–6224 (2001).
15. Crawford, H. C. et al. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol. Cell. Biol. 21, 1370–1383 (2001).
16. Shin, S., Oh, S., An, S. & Janknecht, R. ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells. Oncol. Rep. 29, 306–314 (2013).
17. Kim, T. D. et al. Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. J. Clin. Invest. 126, 706–720 (2016).
18. Janknecht, R. Analysis of the ERK-stimulated ETS transcription factor ER81. Mol. Cell. Biol. 16, 1550–1556 (1996).
19. Wu, J. & Janknecht, R. Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J. Biol. Chem. 277, 42669–42679 (2002).
20. Janknecht, R. Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 22, 746–755 (2003).
21. Sasaki, M. et al. Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol. Cell. Biol. 24, 25–35 (2004).
22. Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003).
23. Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, e59 (2003).
24. Ding, Z. et al. SMAD4-dependent parathyroid constrains prostate cancer growth and metastatic progression. Nature 470, 269–273 (2011).
25. Massague, J. TGFbeta in Cancer. Cell 134, 215–230 (2008).
26. Heldin, C. H. & Möstl, A. Role of Smads in TGFbeta signaling. Cell Tissue Res. 347, 21–36 (2012).
27. Budi, E. H., Duan, D. & Derynck, R. Transforming growth factor-beta receptors and Smads: Regulatory complexity and functional versatility. Trends Cell Biol. 27, 658–672 (2017).
28. Fourrier, P. C. et al. The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell 27, 809–821 (2015).
29. Wallace, T. A. et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927–936 (2008).
30. Holzbeierlein, J. M. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164, 217–227 (2004).
31. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).
32. Yu, Y. P. et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790–2799 (2004).
33. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41–51 (2007).
34. Nakagawa, T. et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 3, e2318 (2008).
35. Zeng, L., Rowland, R. G., Lele, S. M. & Kyriianou, N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum. Pathol. 35, 290–297 (2004).
36. Horvath, L. G. et al. Loss of BMP2, Smad4, and Smad4 expression in prostate cancer progression. Prostate 59, 234–242 (2004).
37. Zhang, D. T., Shi, J. G., Liu, Y. & Jiang, H. M. The prognostic value of Smad4 mRNA in patients with prostate cancer. Tumour Biol. 35, 3333–3337 (2014).
38. Atchison, A. A. et al. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 68, 661–674 (2008).
39. Hayes, S. A. et al. SMAD3 represses androgen receptor-mediated transcription. Cancer Res. 61, 2112–2118 (2001).
40. Kang, H. Y. et al. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc. Natl. Acad. Sci. USA 98, 3018–3023 (2001).
41. Chipuk, J. E. et al. The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J. Biol. Chem. 277, 1240–1248 (2002).
42. Kang, H. Y. et al. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J. Biol. Chem. 277, 43749–43756 (2002).
43. Lu, X. et al. Opposing roles of TGFbeta and BMP signaling in prostate cancer development. Genes Dev. 31, 2337–2342 (2017).
44. Shen, M. M. & Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967–2000 (2010).
45. Tomasetti, C., Marchionni, N., Nowak, M. A., Parmigiani, G. & Vogelstein, B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc. Natl. Acad. Sci. USA 112, 118–123 (2015).
46. Fang, J. et al. Ets related gene and Smad3 proteins collaborate to activate transforming growth factor-beta mediated signaling pathway in ETS related gene-positive prostate cancer cells. J. Pharm. Sci. Pharmacol. 1, 175–181 (2014).
47. Oh, S., Shin, S. & Janknecht, R. ETV1 and 5: An oncogenic subfamily of ETS transcription factors. Biochim. Biophys. Acta 1826, 1–12 (2012).
48. Hellenhorst, R. C., McIntosh, L. P. & Graves, B. J. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu. Rev. Biochem. 80, 437–471 (2011).
49. Kim, T. D., Shin, S., Berry, W. L. & Janknecht, R. The [MJD2A] demethylase regulates apoptosis and proliferation in colon cancer cells. J. Cell. Biol. 113, 1368–1367 (2012).
50. Berry, W. L., Kim, T. D. & Janknecht, R. Stimulation of beta-catenin and colon cancer cell growth by the KDM4B histone demethylase. J. Biol. Chem. 280, 30443–30452 (2010).
51. Mooney, S. M., Grande, J. P., Salisbury, J. L. & Janknecht, R. Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochim. Biophys. Acta 1849, 1–10 (2010).
52. Dowdy, S. C., Mariani, A. & Janknecht, R. HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J. Biol. Chem. 278, 44377–44384 (2003).
53. Goel, A. & Janknecht, R. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/C/AF, and HER2/Neu. Mol. Cell. Biol. 23, 6243–6254 (2003).
54. Kim, T. D., Shin, S. & Janknecht, R. ETS transcription factor ERG cooperates with histone demethylase KDM4A. Oncol. Rep. 35, 3679–3688 (2016).
55. Mooney, S. M., Goel, A., D’Assoro, A. B., Salisbury, J. L. & Janknecht, R. Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. J. Biol. Chem. 285, 30443–30452 (2010).
56. Knebel, J., De Haro, L. & Janknecht, R. Repression of transcription by TSGA/Jmjd1a, a novel interaction partner of the ETS protein ER71. J. Cell. Biochem. 99, 319–329 (2006).
57. Kim, J. et al. Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/1KLF10. Biochim. Biophys. Res. Commun. 401, 412–416 (2010).
58. Papoutsopoulou, S. & Janknecht, R. Phosphorylation of ETS transcription factor ER81 in complex with its coactivators CREB-binding protein and p300. Mol. Cell. Biol. 20, 7300–7310 (2000).
59. Li, X., Moon, G., Shin, S., Zhang, B. & Janknecht, R. Cooperation between ETS variant 2 and Junomii domain-containing 2 histone demethylases. Mol. Med. Rep. 17, 5518–5527 (2018).
60. Li, X. et al. A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer. Oncol. Lett. 16, 6652–6662 (2018).
61. Janknecht, R. & Hanter, T. Activation of the Sap-1 transcription factor by the c-Jun-N-terminal kinase (JNK) mitogen-activated protein kinase. J. Biol. Chem. 272, 4219–4224 (1997).
62. Di Tacco, L. et al. Transcription factors ER71/ETV2 and SOX9 participate in a positive feedback loop in fetal and adult mouse testis. J. Biol. Chem. 287, 23657–23666 (2012).
63. Goel, A. & Janknecht, R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J. Biol. Chem. 279, 14909–14916 (2004).
64. Kim, T. D., Oh, S., Shin, S. & Janknecht, R. Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2B/KDM4D. PLoS One 7, e36418 (2012).
65. Berry, W. L., Shin, S., Lightfoot, S. A. & Janknecht, R. Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int. J. Oncol. 41, 1701–1706 (2012).
66. Kim, T. D. et al. Upregulation of PSMD10 caused by the [MJD2A] histone demethylase. Int. J. Clin. Exp. Med. 9, 10123–10134 (2016).
67. Kim, T. D. et al. Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors. Oncol. Rep. 17, 10495–10504 (2007).
68. Yang, X., Li, C., Herrera, F. L. & Deng, C. X. Generation of Smad4/Dpc4 conditional knockout mice. Genesis 32, 80–81 (2002).
69. Oh, S. & Janknecht, R. Histone demethylase JMJD5 is essential for embryonic development. Biochem. Biophys. Res. Commun. 420, 61–65 (2012).
70. Park, J. H. et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am. J. Pathol. 161, 727–735 (2002).

Acknowledgements

The Stephenson Cancer Center Pathology Core, which performed embedding, sectioning and staining of prostate tissue, has been supported by National Institutes of Health grants P20 GM103639 and P30 CA225520. In addition, this work was partially funded by a postdoctoral fellowship from the Department of Defense Prostate Cancer Research Program (W81XWH-13-1-0083 to S.O.) and by a grant from the National Institutes of Health/National Cancer Institute (R01 CA154745 to R.J.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the granting agencies.
Author Contributions
S.O., S.S., H.S. and R.J. conceived, designed and performed experiments. J.P.G. examined the pathology of mouse prostates. All authors analyzed and interpreted data, contributed to the writing of this manuscript, and approved its final version. R.J. supervised this study.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-44685-3.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019